These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 29675950

  • 1. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database.
    Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Hendrickson JE, NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).
    Br J Haematol; 2018 Jun; 181(5):672-681. PubMed ID: 29675950
    [Abstract] [Full Text] [Related]

  • 2. Alloimmunization in sickle cell anemia in the era of extended red cell typing.
    O'Suoji C, Liem RI, Mack AK, Kingsberry P, Ramsey G, Thompson AA.
    Pediatr Blood Cancer; 2013 Sep; 60(9):1487-91. PubMed ID: 23508932
    [Abstract] [Full Text] [Related]

  • 3. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Sanz C, Nomdedeu M, Belkaid M, Martinez I, Nomdedeu B, Pereira A.
    Transfusion; 2013 Apr; 53(4):710-5. PubMed ID: 22845746
    [Abstract] [Full Text] [Related]

  • 4. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).
    Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE.
    Transfusion; 2019 Jan; 59(1):217-225. PubMed ID: 30427537
    [Abstract] [Full Text] [Related]

  • 5. Screening for new red blood cell alloantibodies after transfusion in patients with sickle cell disease.
    Rankin A, Darbari D, Campbell A, Webb J, Mo YD, Jacquot C, Delaney M, Luban NLC, Nickel RS.
    Transfusion; 2021 Aug; 61(8):2255-2264. PubMed ID: 34002408
    [Abstract] [Full Text] [Related]

  • 6. Red blood cell alloimmunization in sickle cell disease: the influence of racial and antigenic pattern differences between donors and recipients in Brazil.
    Moreira Júnior G, Bordin JO, Kuroda A, Kerbauy J.
    Am J Hematol; 1996 Jul; 52(3):197-200. PubMed ID: 8756087
    [Abstract] [Full Text] [Related]

  • 7. Red blood cell alloimmunization among sickle cell Kuwaiti Arab patients who received red blood cell transfusion.
    Ameen R, Al Shemmari S, Al-Bashir A.
    Transfusion; 2009 Aug; 49(8):1649-54. PubMed ID: 19453992
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease.
    Fasano RM, Booth GS, Miles M, Du L, Koyama T, Meier ER, Luban NL.
    Br J Haematol; 2015 Jan; 168(2):291-300. PubMed ID: 25256676
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease.
    Nickel RS, Hendrickson JE, Yee MM, Bray RA, Gebel HM, Kean LS, Miklos DB, Horan JT.
    Br J Haematol; 2015 Jul; 170(2):247-56. PubMed ID: 25891976
    [Abstract] [Full Text] [Related]

  • 17. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010.
    Miller ST, Kim HY, Weiner DL, Wager CG, Gallagher D, Styles LA, Dampier CD, Roseff SD, Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN).
    Transfusion; 2013 Apr; 53(4):704-9. PubMed ID: 22804353
    [Abstract] [Full Text] [Related]

  • 18. Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance.
    Chhetri R, Wee LYA, Sinha R, Kutyna MM, Pham A, Stathopoulos H, Nath L, Nath SV, Wickham N, Hughes T, Singhal D, Roxby DJ, Hiwase DK.
    Haematologica; 2019 Oct; 104(10):e451-e454. PubMed ID: 30819906
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.